Broad-Spectrum Antibiotics

Azithromycin is an extended-spectrum azalide subclass macrolide antibiotic. It acts by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis without affecting human nucleic acid synthesis. Indicated for community-acquired pneumonia, acute bacterial exacerbations of COPD, bacterial pharyngitis/tonsillitis, acute otitis media, skin and skin structure infections, and uncomplicated genital chlamydial urethritis and cervicitis.

Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.

Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.

Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Cloxacillin combination provides broad-spectrum bactericidal coverage. Amoxycillin targets Gram-negative and Gram-positive non-beta-lactamase producers, while cloxacillin, an isoxazolyl penicillin, resists staphylococcal penicillinases to destroy beta-lactamase-producing Staphylococcus aureus. Often supplemented with Lactic Acid Bacillus (probiotics) to restore normal intestinal flora and mitigate antibiotic-induced diarrhea. Indicated for respiratory tract infections, cellulitis, surgical wound infections, bone/joint infections, and abscesses.

Amoxycillin (Amoxicillin) is a semisynthetic aminopenicillin bactericidal antibiotic. It acts by inhibiting the cross-linking of bacterial peptidoglycan chains in the bacterial cell wall via binding to penicillin-binding proteins (PBPs), leading to autolysis and bacterial cell death. Indicated for uncomplicated ear, nose, and throat infections (streptococcal pharyngitis, acute otitis media), lower respiratory infections, uncomplicated urinary tract infections, and Helicobacter pylori eradication (in combination regimens).

Amoxycillin (Amoxicillin) is a semisynthetic aminopenicillin bactericidal antibiotic. It acts by inhibiting the cross-linking of bacterial peptidoglycan chains in the bacterial cell wall via binding to penicillin-binding proteins (PBPs), leading to autolysis and bacterial cell death. Indicated for uncomplicated ear, nose, and throat infections (streptococcal pharyngitis, acute otitis media), lower respiratory infections, uncomplicated urinary tract infections, and Helicobacter pylori eradication (in combination regimens).

Amoxycillin (Amoxicillin) is a semisynthetic aminopenicillin bactericidal antibiotic. It acts by inhibiting the cross-linking of bacterial peptidoglycan chains in the bacterial cell wall via binding to penicillin-binding proteins (PBPs), leading to autolysis and bacterial cell death. Indicated for uncomplicated ear, nose, and throat infections (streptococcal pharyngitis, acute otitis media), lower respiratory infections, uncomplicated urinary tract infections, and Helicobacter pylori eradication (in combination regimens).

Amoxycillin (Amoxicillin) is a semisynthetic aminopenicillin bactericidal antibiotic. It acts by inhibiting the cross-linking of bacterial peptidoglycan chains in the bacterial cell wall via binding to penicillin-binding proteins (PBPs), leading to autolysis and bacterial cell death. Indicated for uncomplicated ear, nose, and throat infections (streptococcal pharyngitis, acute otitis media), lower respiratory infections, uncomplicated urinary tract infections, and Helicobacter pylori eradication (in combination regimens).

Ampicillin is a broad-spectrum aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), causing cell lysis in susceptible Gram-positive and Gram-negative organisms. Indicated for respiratory tract infections, listeriosis, bacterial meningitis, enterococcal infections, urinary tract infections, and Salmonella infections.

Azithromycin is an extended-spectrum azalide subclass macrolide antibiotic. It acts by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis without affecting human nucleic acid synthesis. Indicated for community-acquired pneumonia, acute bacterial exacerbations of COPD, bacterial pharyngitis/tonsillitis, acute otitis media, skin and skin structure infections, and uncomplicated genital chlamydial urethritis and cervicitis.

Azithromycin is an extended-spectrum azalide subclass macrolide antibiotic. It acts by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis without affecting human nucleic acid synthesis. Indicated for community-acquired pneumonia, acute bacterial exacerbations of COPD, bacterial pharyngitis/tonsillitis, acute otitis media, skin and skin structure infections, and uncomplicated genital chlamydial urethritis and cervicitis.

Cefadroxil is a first-generation oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis. It possesses a prolonged plasma half-life compared to cephalexin, allowing once- or twice-daily dosing. Indicated for streptococcal pharyngitis/tonsillitis, uncomplicated urinary tract infections, and mild-to-moderate skin and skin structure infections.

Cefadroxil is a first-generation oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis. It possesses a prolonged plasma half-life compared to cephalexin, allowing once- or twice-daily dosing. Indicated for streptococcal pharyngitis/tonsillitis, uncomplicated urinary tract infections, and mild-to-moderate skin and skin structure infections.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefoperazone Sodium is a third-generation parenteral cephalosporin bactericidal antibiotic with notable anti-pseudomonal activity. Unlike most cephalosporins, it is predominantly excreted via the bile, making it exceptionally effective for biliary tract infections and useful in patients with renal impairment without routine dose adjustment. Indicated for biliary infections, peritonitis, respiratory tract infections, and sepsis.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Cefotaxime Sodium and Sulbactam Sodium is a parenteral combination of a third-generation cephalosporin and a beta-lactamase inhibitor. Cefotaxime inhibits bacterial cell wall synthesis with exceptional activity against Gram-negative bacilli and Streptococcus pneumoniae, while sulbactam neutralizes beta-lactamases produced by resistant pathogens. Indicated for severe intra-abdominal infections, septicemia, meningitis, hospital-acquired pneumonia, and bone and joint infections.

Cefotaxime Sodium is a third-generation parenteral cephalosporin bactericidal antibiotic. It binds to PBPs to inhibit peptidoglycan synthesis. Features high cerebrospinal fluid (CSF) penetration, making it an essential first-line agent for bacterial meningitis. Also indicated for severe sepsis, bacteremia, peritonitis, complicated urinary tract infections, and lower respiratory infections.

Cefotaxime Sodium is a third-generation parenteral cephalosporin bactericidal antibiotic. It binds to PBPs to inhibit peptidoglycan synthesis. Features high cerebrospinal fluid (CSF) penetration, making it an essential first-line agent for bacterial meningitis. Also indicated for severe sepsis, bacteremia, peritonitis, complicated urinary tract infections, and lower respiratory infections.

Cefotaxime Sodium is a third-generation parenteral cephalosporin bactericidal antibiotic. It binds to PBPs to inhibit peptidoglycan synthesis. Features high cerebrospinal fluid (CSF) penetration, making it an essential first-line agent for bacterial meningitis. Also indicated for severe sepsis, bacteremia, peritonitis, complicated urinary tract infections, and lower respiratory infections.

Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.

Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Ceftriaxone Sodium and Tazobactam Sodium combines an extended-spectrum third-generation cephalosporin with the potent beta-lactamase inhibitor tazobactam. Tazobactam prevents ceftriaxone hydrolysis by plasmid- and chromosome-mediated beta-lactamases, restoring full bactericidal activity. Indicated for severe polymicrobial infections, meningitis, sepsis, complicated skin/soft tissue infections, and hospital-acquired lower respiratory infections.

Azithromycin is an extended-spectrum azalide subclass macrolide antibiotic. It acts by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis without affecting human nucleic acid synthesis. Indicated for community-acquired pneumonia, acute bacterial exacerbations of COPD, bacterial pharyngitis/tonsillitis, acute otitis media, skin and skin structure infections, and uncomplicated genital chlamydial urethritis and cervicitis.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Ceftriaxone Sodium and Sulbactam Sodium is a synergistic parenteral bactericidal formulation. Ceftriaxone provides broad-spectrum third-generation cephalosporin bactericidal action with a prolonged half-life, while sulbactam irreversibly inhibits beta-lactamases, overcoming resistance in ESBL-producing enterobacteriaceae and Acinetobacter. Indicated for severe community- and hospital-acquired pneumonia, sepsis, complicated intra-abdominal infections, pyelonephritis, and surgical prophylaxis.

Ceftriaxone Sodium is an essential third-generation parenteral cephalosporin bactericidal antibiotic on the WHO Model List of Essential Medicines. It features an exceptionally long elimination half-life (around 8 hours), permitting once-daily administration. Crosses the blood-brain barrier effectively. Indicated for bacterial meningitis, septicemia, community-acquired pneumonia, typhoid fever, complicated UTIs, gonococcal infections, pelvic inflammatory disease, and pre-operative surgical prophylaxis.

Ceftriaxone Sodium is an essential third-generation parenteral cephalosporin bactericidal antibiotic on the WHO Model List of Essential Medicines. It features an exceptionally long elimination half-life (around 8 hours), permitting once-daily administration. Crosses the blood-brain barrier effectively. Indicated for bacterial meningitis, septicemia, community-acquired pneumonia, typhoid fever, complicated UTIs, gonococcal infections, pelvic inflammatory disease, and pre-operative surgical prophylaxis.

Ceftriaxone Sodium is an essential third-generation parenteral cephalosporin bactericidal antibiotic on the WHO Model List of Essential Medicines. It features an exceptionally long elimination half-life (around 8 hours), permitting once-daily administration. Crosses the blood-brain barrier effectively. Indicated for bacterial meningitis, septicemia, community-acquired pneumonia, typhoid fever, complicated UTIs, gonococcal infections, pelvic inflammatory disease, and pre-operative surgical prophylaxis.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Cephalexin is a classic first-generation oral cephalosporin antibiotic. It exerts bactericidal action by inhibiting transpeptidase enzymes involved in the final stages of bacterial cell wall synthesis. Demonstrates strong in vitro activity against susceptible Staphylococcus aureus (methicillin-sensitive), Streptococcus pneumoniae, Streptococcus pyogenes, and Escherichia coli. Indicated for respiratory tract infections, otitis media, skin and soft tissue infections, and uncomplicated cystitis.

Cephalexin is a classic first-generation oral cephalosporin antibiotic. It exerts bactericidal action by inhibiting transpeptidase enzymes involved in the final stages of bacterial cell wall synthesis. Demonstrates strong in vitro activity against susceptible Staphylococcus aureus (methicillin-sensitive), Streptococcus pneumoniae, Streptococcus pyogenes, and Escherichia coli. Indicated for respiratory tract infections, otitis media, skin and soft tissue infections, and uncomplicated cystitis.

Cephalexin is a classic first-generation oral cephalosporin antibiotic. It exerts bactericidal action by inhibiting transpeptidase enzymes involved in the final stages of bacterial cell wall synthesis. Demonstrates strong in vitro activity against susceptible Staphylococcus aureus (methicillin-sensitive), Streptococcus pneumoniae, Streptococcus pyogenes, and Escherichia coli. Indicated for respiratory tract infections, otitis media, skin and soft tissue infections, and uncomplicated cystitis.

Ciprofloxacin and Tinidazole is a broad-spectrum dual antimicrobial combination. Ciprofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, targeting aerobic Gram-negative and Gram-positive bacteria, while tinidazole, a second-generation nitroimidazole, generates free nitro-radicals that damage protozoal and anaerobic DNA. Indicated for mixed aerobic-anaerobic bacterial and protozoal infections, including amoebiasis, giardiasis, bacterial dysentery, pelvic inflammatory disease, and dental abscesses.

Ciprofloxacin and Tinidazole is a broad-spectrum dual antimicrobial combination. Ciprofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, targeting aerobic Gram-negative and Gram-positive bacteria, while tinidazole, a second-generation nitroimidazole, generates free nitro-radicals that damage protozoal and anaerobic DNA. Indicated for mixed aerobic-anaerobic bacterial and protozoal infections, including amoebiasis, giardiasis, bacterial dysentery, pelvic inflammatory disease, and dental abscesses.

Ciprofloxacin Hydrochloride is a potent second-generation fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair. Possesses exceptional activity against aerobic Gram-negative bacilli, including Pseudomonas aeruginosa, Salmonella, Shigella, and Escherichia coli. Indicated for complicated urinary tract infections, pyelonephritis, infectious diarrhea/typhoid, chronic bacterial prostatitis, and bone/joint infections.

Ciprofloxacin Hydrochloride is a potent second-generation fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair. Possesses exceptional activity against aerobic Gram-negative bacilli, including Pseudomonas aeruginosa, Salmonella, Shigella, and Escherichia coli. Indicated for complicated urinary tract infections, pyelonephritis, infectious diarrhea/typhoid, chronic bacterial prostatitis, and bone/joint infections.

Co-trimoxazole is a fixed-ratio (5:1) synergistic antibacterial combination of Sulphamethoxazole (SMX) and Trimethoprim (TMP). SMX competitively inhibits bacterial dihydropteroate synthase, while TMP inhibits dihydrofolate reductase, sequentially blocking two consecutive steps in bacterial tetrahydrofolate synthesis. Indicated for urinary tract infections, acute otitis media, Shigella enteritis, Pneumocystis jirovecii pneumonia (PJP) treatment and prophylaxis, and community-acquired MRSA skin infections.

Co-trimoxazole is a fixed-ratio (5:1) synergistic antibacterial combination of Sulphamethoxazole (SMX) and Trimethoprim (TMP). SMX competitively inhibits bacterial dihydropteroate synthase, while TMP inhibits dihydrofolate reductase, sequentially blocking two consecutive steps in bacterial tetrahydrofolate synthesis. Indicated for urinary tract infections, acute otitis media, Shigella enteritis, Pneumocystis jirovecii pneumonia (PJP) treatment and prophylaxis, and community-acquired MRSA skin infections.

Co-trimoxazole is a fixed-ratio (5:1) synergistic antibacterial combination of Sulphamethoxazole (SMX) and Trimethoprim (TMP). SMX competitively inhibits bacterial dihydropteroate synthase, while TMP inhibits dihydrofolate reductase, sequentially blocking two consecutive steps in bacterial tetrahydrofolate synthesis. Indicated for urinary tract infections, acute otitis media, Shigella enteritis, Pneumocystis jirovecii pneumonia (PJP) treatment and prophylaxis, and community-acquired MRSA skin infections.

Doxycycline is a broad-spectrum, long-acting synthetic tetracycline antibiotic. It acts by reversibly binding to the 30S bacterial ribosomal subunit, preventing the binding of aminoacyl-tRNA to the ribosomal acceptor site and halting protein synthesis. Possesses anti-inflammatory properties by inhibiting matrix metalloproteinases. Indicated for rickettsial infections (scrub typhus, Rocky Mountain spotted fever), chlamydial infections, acne vulgaris, malaria prophylaxis, respiratory tract infections (atypical pneumonia), and Lyme disease.

Erythromycin is the prototypical macrolide antibiotic produced by Saccharopolyspora erythraea. It inhibits protein synthesis by binding to the 50S ribosomal subunit. Effective against Gram-positive bacteria, atypical pathogens, and Bordetella pertussis. Indicated for respiratory tract infections, pertussis, diphtheria, syphilis in penicillin-allergic patients, and prophylaxis of neonatal chlamydial conjunctivitis.

Gentamicin Sulphate is a bactericidal aminoglycoside antibiotic produced by Micromonospora purpurea. It acts by binding to the 30S bacterial ribosome, disrupting protein elongation and destabilizing bacterial cell membranes. Used in the management of severe systemic infections, including sepsis, complicated intra-abdominal infections, pyelonephritis, endocarditis (in synergy with beta-lactams), and pelvic inflammatory disease caused by susceptible aerobic Gram-negative pathogens.

Levofloxacin is the active S-(-)-enantiomer of the fluoroquinolone ofloxacin. It exerts potent bactericidal activity by inhibiting bacterial topoisomerase IV and DNA gyrase, demonstrating 8- to 128-fold higher potency than the R-enantiomer against respiratory and systemic pathogens. High bioavailability allows 1:1 oral-to-intravenous conversion. Indicated for community-acquired and nosocomial pneumonia, acute pyelonephritis, complicated skin infections, chronic bacterial prostatitis, and multidrug-resistant tuberculosis.

Levofloxacin is the active S-(-)-enantiomer of the fluoroquinolone ofloxacin. It exerts potent bactericidal activity by inhibiting bacterial topoisomerase IV and DNA gyrase, demonstrating 8- to 128-fold higher potency than the R-enantiomer against respiratory and systemic pathogens. High bioavailability allows 1:1 oral-to-intravenous conversion. Indicated for community-acquired and nosocomial pneumonia, acute pyelonephritis, complicated skin infections, chronic bacterial prostatitis, and multidrug-resistant tuberculosis.

Meropenem is an intravenous synthetic carbapenem bactericidal antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic pathogens. It acts by inhibiting bacterial cell wall synthesis via high-affinity binding to essential PBPs (PBP 2, 3, and 4). Has low epileptogenic potential compared to imipenem. Indicated for complicated intra-abdominal infections, complicated skin and soft tissue infections, bacterial meningitis in paediatric and adult patients, nosocomial pneumonia, and febrile neutropenia.

Norfloxacin is a fluoroquinolone antibacterial agent that acts by inhibiting bacterial DNA gyrase. Due to limited systemic absorption and high concentrations achieved in urine and the gastrointestinal tract, its clinical utility is focused specifically on urinary tract infections and enteric pathogens. Indicated for uncomplicated and complicated urinary tract infections, bacterial prostatitis, and acute bacterial gastroenteritis (traveler's diarrhea).

Ofloxacin and Ornidazole is a broad-spectrum fixed-dose antimicrobial combination pairing a fluoroquinolone with a nitroimidazole. Ofloxacin halts bacterial DNA multiplication, while ornidazole damages microbial DNA through free nitro radicals, eradicating anaerobes and protozoa. Indicated for mixed bacterial and protozoal gastroenteritis, amoebic dysentery, pelvic inflammatory disease, dental infections, and post-surgical abdominal sepsis.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Piperacillin and Tazobactam is an extended-spectrum ureidopenicillin combined with a beta-lactamase inhibitor. Piperacillin exhibits potent bactericidal activity against Pseudomonas aeruginosa, Enterobacteriaceae, and anaerobes by inhibiting cell wall synthesis, while tazobactam inactivates plasmid- and chromosomally-mediated beta-lactamases. Indicated for nosocomial and severe community-acquired pneumonia, complicated intra-abdominal infections, complicated skin/soft tissue infections, febrile neutropenia, and complicated urinary tract infections.

Roxithromycin is a semi-synthetic 14-membered macrolide antibiotic with high oral bioavailability and superior acid stability compared to erythromycin. It reversibly binds to the 50S bacterial ribosome to block peptide chain elongation. Indicated for respiratory tract infections (pharyngitis, tonsillitis, sinusitis, pneumonia), otitis media, and skin/soft tissue infections.

Roxithromycin is a semi-synthetic 14-membered macrolide antibiotic with high oral bioavailability and superior acid stability compared to erythromycin. It reversibly binds to the 50S bacterial ribosome to block peptide chain elongation. Indicated for respiratory tract infections (pharyngitis, tonsillitis, sinusitis, pneumonia), otitis media, and skin/soft tissue infections.

Tinidazole is a second-generation 5-nitroimidazole antimicrobial agent with a significantly longer elimination half-life (12-14 hours) than metronidazole, allowing once-daily dosing. It diffuses into microorganisms where its nitro group is reduced, creating free radicals that cause DNA strand breakage. Indicated for intestinal and hepatic amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, and prevention/treatment of postoperative anaerobic infections.

Tinidazole is a second-generation 5-nitroimidazole antimicrobial agent with a significantly longer elimination half-life (12-14 hours) than metronidazole, allowing once-daily dosing. It diffuses into microorganisms where its nitro group is reduced, creating free radicals that cause DNA strand breakage. Indicated for intestinal and hepatic amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, and prevention/treatment of postoperative anaerobic infections.

Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.

Ciprofloxacin Hydrochloride is a potent second-generation fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair. Possesses exceptional activity against aerobic Gram-negative bacilli, including Pseudomonas aeruginosa, Salmonella, Shigella, and Escherichia coli. Indicated for complicated urinary tract infections, pyelonephritis, infectious diarrhea/typhoid, chronic bacterial prostatitis, and bone/joint infections.

Metronidazole is a synthetic nitroimidazole antimicrobial on the WHO Model List of Essential Medicines. It enters microbial cells via passive diffusion, where its nitro group is reduced by microbial ferredoxin to generate cytotoxic nitro radicals that disrupt helical DNA structure, leading to cell death. Highly effective against obligate anaerobes (Bacteroides, Clostridium) and protozoa (Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis). Indicated for amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, anaerobic surgical sepsis, and H. pylori eradication.

Metronidazole is a synthetic nitroimidazole antimicrobial on the WHO Model List of Essential Medicines. It enters microbial cells via passive diffusion, where its nitro group is reduced by microbial ferredoxin to generate cytotoxic nitro radicals that disrupt helical DNA structure, leading to cell death. Highly effective against obligate anaerobes (Bacteroides, Clostridium) and protozoa (Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis). Indicated for amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, anaerobic surgical sepsis, and H. pylori eradication.

Metronidazole is a synthetic nitroimidazole antimicrobial on the WHO Model List of Essential Medicines. It enters microbial cells via passive diffusion, where its nitro group is reduced by microbial ferredoxin to generate cytotoxic nitro radicals that disrupt helical DNA structure, leading to cell death. Highly effective against obligate anaerobes (Bacteroides, Clostridium) and protozoa (Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis). Indicated for amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis, anaerobic surgical sepsis, and H. pylori eradication.

Ornidazole is a synthetic nitroimidazole antiprotozoal and antibacterial agent. It is activated inside protozoa and anaerobic bacteria to form reactive reduced intermediates that interact with DNA, inhibiting nucleic acid synthesis. Indicated for acute amoebic dysentery, amoebic liver abscess, giardiasis, trichomoniasis, and anaerobic surgical and dental infections.

Imipenem and Cilastatin is a broad-spectrum carbapenem antibiotic formulated with an enzyme inhibitor. Imipenem provides potent bactericidal action by inhibiting bacterial cell wall synthesis, while cilastatin inhibits renal dehydropeptidase-I (DHP-I) in the renal brush border, preventing renal metabolism of imipenem, blocking nephrotoxic metabolites, and maintaining high urinary drug concentrations. Indicated for severe polymicrobial infections, hospital-acquired pneumonia, sepsis, intra-abdominal infections, and complicated UTIs.

Clindamycin is a lincosamide class bacteriostatic and bactericidal antibiotic. It binds reversibly to the 50S ribosomal subunit of susceptible microorganisms, inhibiting bacterial protein synthesis. Displays potent coverage against Gram-positive anaerobes, Bacteroides fragilis, and methicillin-resistant Staphylococcus aureus (MRSA). Indicated for serious skin and soft tissue infections, osteomyelitis, dental abscesses, pelvic inflammatory disease, and aspiration pneumonia.

Clarithromycin is an advanced semi-synthetic macrolide antibiotic. It binds to the 50S ribosomal subunit, preventing protein synthesis, and is metabolized into an active 14-hydroxyclarithromycin metabolite with enhanced bactericidal activity against Haemophilus influenzae. Indicated for community-acquired pneumonia, pharyngitis/tonsillitis, acute sinusitis, skin infections, Mycobacterium avium complex (MAC) in HIV, and H. pylori eradication in triple therapy.

Cefixime and Ofloxacin is a fixed-dose combination antibiotic combining a 3rd-generation cephalosporin and a broad-spectrum fluoroquinolone. Cefixime inhibits cell wall synthesis, while ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, halting DNA replication. This dual mechanism provides synergistic bactericidal coverage against resistant pathogens. Indicated for enteric fever (typhoid fever), severe respiratory tract infections, complicated urinary tract infections, and mixed bacterial pelvic infections.

Linezolid is a synthetic oxazolidinone antibacterial agent on the WHO Model List of Essential Medicines. It possesses a unique mechanism of action, binding to the 23S ribosomal RNA of the 50S subunit and preventing formation of the functional 70S initiation complex, precluding cross-resistance with other protein synthesis inhibitors. Demonstrates 100% oral bioavailability. Indicated for vancomycin-resistant Enterococcus faecium (VRE), hospital-acquired and community-acquired MRSA pneumonia, and complicated skin and soft tissue infections.

Cefpodoxime Proxetil and Potassium Clavulanate combines a third-generation cephalosporin with a beta-lactamase inhibitor. Clavulanic acid shields cefpodoxime from degradation by beta-lactamases produced by Staphylococcus aureus, H. influenzae, and enterobacteria. Indicated for community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, recurrent otitis media, and skin/soft tissue infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic with enhanced bactericidal activity against Gram-positive bacteria (including penicillin-resistant Streptococcus pneumoniae) and anaerobes, alongside standard Gram-negative coverage. It does not require dosage adjustments in renal impairment because it is eliminated primarily by hepatic glucuronide and sulfate conjugation. Indicated for community-acquired pneumonia, acute bacterial sinusitis, complicated intra-abdominal infections, and second-line MDR-TB regimens.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Clindamycin is a lincosamide class bacteriostatic and bactericidal antibiotic. It binds reversibly to the 50S ribosomal subunit of susceptible microorganisms, inhibiting bacterial protein synthesis. Displays potent coverage against Gram-positive anaerobes, Bacteroides fragilis, and methicillin-resistant Staphylococcus aureus (MRSA). Indicated for serious skin and soft tissue infections, osteomyelitis, dental abscesses, pelvic inflammatory disease, and aspiration pneumonia.

Linezolid is a synthetic oxazolidinone antibacterial agent on the WHO Model List of Essential Medicines. It possesses a unique mechanism of action, binding to the 23S ribosomal RNA of the 50S subunit and preventing formation of the functional 70S initiation complex, precluding cross-resistance with other protein synthesis inhibitors. Demonstrates 100% oral bioavailability. Indicated for vancomycin-resistant Enterococcus faecium (VRE), hospital-acquired and community-acquired MRSA pneumonia, and complicated skin and soft tissue infections.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Rifaximin is a non-systemic, gut-selective rifamycin-class antibacterial agent. It acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking bacterial RNA transcription. Oral bioavailability is less than 0.4%, ensuring minimal systemic absorption and concentrating therapeutic power within the intestinal lumen without disturbing extraintestinal flora. Indicated for traveler's diarrhea (caused by non-invasive E. coli), reduction in risk of overt hepatic encephalopathy recurrence, and irritable bowel syndrome with diarrhea (IBS-D).

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Clotrimazole Vaginal Tablet is a broad-spectrum imidazole antifungal agent. It acts by inhibiting fungal cytochrome P450 enzyme 14-alpha-demethylase, blocking the conversion of lanosterol to ergosterol. The resulting depletion of ergosterol and accumulation of toxic methylsterols disrupts fungal cell membrane integrity, resulting in cell lysis of Candida albicans and other Candida species. Indicated for vulvovaginal candidiasis (vaginal yeast infection).

Cephalexin is a classic first-generation oral cephalosporin antibiotic. It exerts bactericidal action by inhibiting transpeptidase enzymes involved in the final stages of bacterial cell wall synthesis. Demonstrates strong in vitro activity against susceptible Staphylococcus aureus (methicillin-sensitive), Streptococcus pneumoniae, Streptococcus pyogenes, and Escherichia coli. Indicated for respiratory tract infections, otitis media, skin and soft tissue infections, and uncomplicated cystitis.

Levofloxacin is the active S-(-)-enantiomer of the fluoroquinolone ofloxacin. It exerts potent bactericidal activity by inhibiting bacterial topoisomerase IV and DNA gyrase, demonstrating 8- to 128-fold higher potency than the R-enantiomer against respiratory and systemic pathogens. High bioavailability allows 1:1 oral-to-intravenous conversion. Indicated for community-acquired and nosocomial pneumonia, acute pyelonephritis, complicated skin infections, chronic bacterial prostatitis, and multidrug-resistant tuberculosis.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Clarithromycin is an advanced semi-synthetic macrolide antibiotic. It binds to the 50S ribosomal subunit, preventing protein synthesis, and is metabolized into an active 14-hydroxyclarithromycin metabolite with enhanced bactericidal activity against Haemophilus influenzae. Indicated for community-acquired pneumonia, pharyngitis/tonsillitis, acute sinusitis, skin infections, Mycobacterium avium complex (MAC) in HIV, and H. pylori eradication in triple therapy.

Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.

Cefuroxime (as Cefuroxime Axetil for oral use or Cefuroxime Sodium for parenteral use) is a second-generation cephalosporin antibiotic. It resists degradation by many bacterial beta-lactamases and possesses bactericidal action against a broad spectrum of Gram-positive and Gram-negative organisms, including beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. pneumoniae, and S. aureus. Indicated for acute bacterial sinusitis, tonsillitis, acute otitis media, acute exacerbations of chronic bronchitis, uncomplicated UTIs, early Lyme disease, and surgical prophylaxis.

Cefaclor is a second-generation oral cephalosporin antibiotic. It exhibits bactericidal activity against both Gram-positive cocci and common Gram-negative respiratory pathogens, including Haemophilus influenzae and Moraxella catarrhalis. Indicated for acute otitis media, lower respiratory tract infections (bronchitis, pneumonia), pharyngitis, tonsillitis, and uncomplicated urinary tract infections.

Ampicillin is a broad-spectrum aminopenicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), causing cell lysis in susceptible Gram-positive and Gram-negative organisms. Indicated for respiratory tract infections, listeriosis, bacterial meningitis, enterococcal infections, urinary tract infections, and Salmonella infections.

Faropenem Sodium is an orally active penem beta-lactam antibiotic. It possesses broad-spectrum bactericidal activity against Gram-positive, Gram-negative, and anaerobic pathogens by binding to high-molecular-weight penicillin-binding proteins. Exhibits exceptional stability against diverse beta-lactamases (both penicillinases and cephalosporinases). Indicated for upper and lower respiratory tract infections, uncomplicated and complicated urinary tract infections, and skin/soft tissue infections.

Meropenem and Sulbactam is a potent ultra-broad-spectrum parenteral carbapenem-beta-lactamase inhibitor combination. Meropenem resists degradation by renal dehydropeptidase-1 and binds penicillin-binding proteins with high affinity, while sulbactam neutralizes beta-lactamases and exerts direct bactericidal activity against Acinetobacter baumannii. Indicated for life-threatening nosocomial infections, ventilator-associated pneumonia, septicemia, complicated intra-abdominal infections, and severe surgical sepsis caused by MDR pathogens.

Meropenem is an intravenous synthetic carbapenem bactericidal antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic pathogens. It acts by inhibiting bacterial cell wall synthesis via high-affinity binding to essential PBPs (PBP 2, 3, and 4). Has low epileptogenic potential compared to imipenem. Indicated for complicated intra-abdominal infections, complicated skin and soft tissue infections, bacterial meningitis in paediatric and adult patients, nosocomial pneumonia, and febrile neutropenia.

Teicoplanin is a parenteral glycopeptide antibiotic with bactericidal activity against aerobic and anaerobic Gram-positive bacteria, including MRSA and Enterococcus faecalis. Like vancomycin, it inhibits peptidoglycan polymerization by binding to D-Ala-D-Ala residues, but features a significantly longer half-life (up to 100 hours), allowing once-daily dosing and intramuscular administration without the risk of Red Man Syndrome. Indicated for complicated skin and soft tissue infections, osteomyelitis, septic arthritis, hospital-acquired pneumonia, and endocarditis.

Tigecycline is a first-in-class glycylcycline antibiotic structurally derived from minocycline. It circumvents major tetracycline resistance mechanisms (efflux pumps and ribosomal protection) by binding to the 30S ribosomal subunit with 5-fold higher affinity. Displays broad activity against multidrug-resistant pathogens including MRSA, VRE, ESBL-producing enterobacteria, and carbapenem-resistant Acinetobacter. Indicated for complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Dicloxacillin is a dual bactericidal penicillin formulation engineered to conquer mixed bacterial infections. Amoxycillin inhibits bacterial cell wall synthesis across broad bacterial spectra, while dicloxacillin resists staphylococcal penicillinase degradation. Often formulated with Lactic Acid Bacillus to prevent disruption of gastrointestinal microbiota. Indicated for skin and soft tissue infections, wound sepsis, upper and lower respiratory infections, and post-surgical prophylaxis.

Ampicillin and Cloxacillin combination (often termed Ampiclox) provides dual bactericidal action against a wide range of Gram-positive and Gram-negative pathogens, including penicillinase-producing Staphylococci. Ampicillin targets sensitive streptococci, enterococci, and Gram-negative bacilli, while cloxacillin resists destruction by staphylococcal beta-lactamases. Indicated for respiratory tract infections, puerperal sepsis, wound infections, and post-surgical prophylaxis.

Ampicillin and Cloxacillin combination (often termed Ampiclox) provides dual bactericidal action against a wide range of Gram-positive and Gram-negative pathogens, including penicillinase-producing Staphylococci. Ampicillin targets sensitive streptococci, enterococci, and Gram-negative bacilli, while cloxacillin resists destruction by staphylococcal beta-lactamases. Indicated for respiratory tract infections, puerperal sepsis, wound infections, and post-surgical prophylaxis.

Azithromycin is an extended-spectrum azalide subclass macrolide antibiotic. It acts by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis without affecting human nucleic acid synthesis. Indicated for community-acquired pneumonia, acute bacterial exacerbations of COPD, bacterial pharyngitis/tonsillitis, acute otitis media, skin and skin structure infections, and uncomplicated genital chlamydial urethritis and cervicitis.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefoperazone Sodium and Sulbactam Sodium is a high-potency parenteral combination targeting resistant Gram-negative bacilli and anaerobes. Cefoperazone offers broad anti-pseudomonal and Gram-negative bactericidal coverage excreted primarily via the biliary route, while sulbactam inhibits beta-lactamases and possesses intrinsic activity against Acinetobacter baumannii. Indicated for intra-abdominal infections, biliary tract sepsis, hospital-acquired pneumonia, gynecological infections, and polymicrobial bacteremia.

Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.

Ceftriaxone Sodium and Tazobactam Sodium combines an extended-spectrum third-generation cephalosporin with the potent beta-lactamase inhibitor tazobactam. Tazobactam prevents ceftriaxone hydrolysis by plasmid- and chromosome-mediated beta-lactamases, restoring full bactericidal activity. Indicated for severe polymicrobial infections, meningitis, sepsis, complicated skin/soft tissue infections, and hospital-acquired lower respiratory infections.

Ceftriaxone Sodium is an essential third-generation parenteral cephalosporin bactericidal antibiotic on the WHO Model List of Essential Medicines. It features an exceptionally long elimination half-life (around 8 hours), permitting once-daily administration. Crosses the blood-brain barrier effectively. Indicated for bacterial meningitis, septicemia, community-acquired pneumonia, typhoid fever, complicated UTIs, gonococcal infections, pelvic inflammatory disease, and pre-operative surgical prophylaxis.

Cephalexin is a classic first-generation oral cephalosporin antibiotic. It exerts bactericidal action by inhibiting transpeptidase enzymes involved in the final stages of bacterial cell wall synthesis. Demonstrates strong in vitro activity against susceptible Staphylococcus aureus (methicillin-sensitive), Streptococcus pneumoniae, Streptococcus pyogenes, and Escherichia coli. Indicated for respiratory tract infections, otitis media, skin and soft tissue infections, and uncomplicated cystitis.

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic produced by Streptomyces venezuelae. It reversibly binds to the 50S subunit of the 70S bacterial ribosome, inhibiting peptidyl transferase and peptide bond formation. Penetrates CSF, eye, and tissues exceptionally well. Because of serious toxicity risks, systemic use is strictly restricted to life-threatening infections where safer alternatives are ineffective or contraindicated, including bacterial meningitis and severe typhoid fever.

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic produced by Streptomyces venezuelae. It reversibly binds to the 50S subunit of the 70S bacterial ribosome, inhibiting peptidyl transferase and peptide bond formation. Penetrates CSF, eye, and tissues exceptionally well. Because of serious toxicity risks, systemic use is strictly restricted to life-threatening infections where safer alternatives are ineffective or contraindicated, including bacterial meningitis and severe typhoid fever.

Ciprofloxacin and Dexamethasone is an antibacterial and anti-inflammatory combination for topical ophthalmic and otic administration. Ciprofloxacin eradicates susceptible ocular and otic bacterial pathogens by inhibiting DNA gyrase, while dexamethasone, a potent corticosteroid, suppresses inflammatory edema, pain, redness, and itching. Indicated for acute otitis media with tympanostomy tubes, acute otitis externa, and bacterial conjunctivitis or post-operative ocular inflammation.

Colistimethate Sodium (Colistin) is a polymyxin bactericidal antibiotic (Polymyxin E). It functions as a cationic detergent that binds to lipopolysaccharides and phospholipids in the outer cell membrane of Gram-negative bacteria, disrupting membrane integrity and causing leakage of intracellular contents. Serves as a critical reserve antibiotic for severe, life-threatening infections caused by carbapenem-resistant Gram-negative pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae).

Colistimethate Sodium (Colistin) is a polymyxin bactericidal antibiotic (Polymyxin E). It functions as a cationic detergent that binds to lipopolysaccharides and phospholipids in the outer cell membrane of Gram-negative bacteria, disrupting membrane integrity and causing leakage of intracellular contents. Serves as a critical reserve antibiotic for severe, life-threatening infections caused by carbapenem-resistant Gram-negative pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae).

Colistimethate Sodium (Colistin) is a polymyxin bactericidal antibiotic (Polymyxin E). It functions as a cationic detergent that binds to lipopolysaccharides and phospholipids in the outer cell membrane of Gram-negative bacteria, disrupting membrane integrity and causing leakage of intracellular contents. Serves as a critical reserve antibiotic for severe, life-threatening infections caused by carbapenem-resistant Gram-negative pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae).

Erythromycin is the prototypical macrolide antibiotic produced by Saccharopolyspora erythraea. It inhibits protein synthesis by binding to the 50S ribosomal subunit. Effective against Gram-positive bacteria, atypical pathogens, and Bordetella pertussis. Indicated for respiratory tract infections, pertussis, diphtheria, syphilis in penicillin-allergic patients, and prophylaxis of neonatal chlamydial conjunctivitis.

Rifaximin is a non-systemic, gut-selective rifamycin-class antibacterial agent. It acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking bacterial RNA transcription. Oral bioavailability is less than 0.4%, ensuring minimal systemic absorption and concentrating therapeutic power within the intestinal lumen without disturbing extraintestinal flora. Indicated for traveler's diarrhea (caused by non-invasive E. coli), reduction in risk of overt hepatic encephalopathy recurrence, and irritable bowel syndrome with diarrhea (IBS-D).

Rifaximin is a non-systemic, gut-selective rifamycin-class antibacterial agent. It acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking bacterial RNA transcription. Oral bioavailability is less than 0.4%, ensuring minimal systemic absorption and concentrating therapeutic power within the intestinal lumen without disturbing extraintestinal flora. Indicated for traveler's diarrhea (caused by non-invasive E. coli), reduction in risk of overt hepatic encephalopathy recurrence, and irritable bowel syndrome with diarrhea (IBS-D).

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Potassium Clavulanate is a synergistic broad-spectrum antibacterial combination. Amoxycillin, an extended-spectrum aminopenicillin, inhibits bacterial cell wall peptidoglycan synthesis, while clavulanic acid, a beta-lactamase inhibitor, competitively binds and inactivates beta-lactamase enzymes produced by resistant bacteria, thereby safeguarding amoxycillin from enzymatic degradation. Indicated for acute otitis media, bacterial sinusitis, community-acquired pneumonia, skin and skin structure infections, recurrent urinary tract infections, and post-operative dental and surgical infections.

Amoxycillin and Cloxacillin combination provides broad-spectrum bactericidal coverage. Amoxycillin targets Gram-negative and Gram-positive non-beta-lactamase producers, while cloxacillin, an isoxazolyl penicillin, resists staphylococcal penicillinases to destroy beta-lactamase-producing Staphylococcus aureus. Often supplemented with Lactic Acid Bacillus (probiotics) to restore normal intestinal flora and mitigate antibiotic-induced diarrhea. Indicated for respiratory tract infections, cellulitis, surgical wound infections, bone/joint infections, and abscesses.

Amoxycillin and Cloxacillin combination provides broad-spectrum bactericidal coverage. Amoxycillin targets Gram-negative and Gram-positive non-beta-lactamase producers, while cloxacillin, an isoxazolyl penicillin, resists staphylococcal penicillinases to destroy beta-lactamase-producing Staphylococcus aureus. Often supplemented with Lactic Acid Bacillus (probiotics) to restore normal intestinal flora and mitigate antibiotic-induced diarrhea. Indicated for respiratory tract infections, cellulitis, surgical wound infections, bone/joint infections, and abscesses.

Amoxycillin and Dicloxacillin is a dual bactericidal penicillin formulation engineered to conquer mixed bacterial infections. Amoxycillin inhibits bacterial cell wall synthesis across broad bacterial spectra, while dicloxacillin resists staphylococcal penicillinase degradation. Often formulated with Lactic Acid Bacillus to prevent disruption of gastrointestinal microbiota. Indicated for skin and soft tissue infections, wound sepsis, upper and lower respiratory infections, and post-surgical prophylaxis.

Cefdinir is an extended-spectrum third-generation oral cephalosporin antibiotic. It binds to penicillin-binding proteins, inhibiting bacterial cell wall synthesis. Highly stable to many plasmid-mediated beta-lactamases. Indicated for community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and acute otitis media in paediatric patients.

Cefdinir is an extended-spectrum third-generation oral cephalosporin antibiotic. It binds to penicillin-binding proteins, inhibiting bacterial cell wall synthesis. Highly stable to many plasmid-mediated beta-lactamases. Indicated for community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and acute otitis media in paediatric patients.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefprozil is a second-generation oral cephalosporin with broad-spectrum bactericidal activity. It provides enhanced stability against certain beta-lactamases and active coverage against Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis. Indicated for acute sinusitis, otitis media, secondary bacterial infections of acute bronchitis, community-acquired pneumonia, and uncomplicated skin infections.

Cefprozil is a second-generation oral cephalosporin with broad-spectrum bactericidal activity. It provides enhanced stability against certain beta-lactamases and active coverage against Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis. Indicated for acute sinusitis, otitis media, secondary bacterial infections of acute bronchitis, community-acquired pneumonia, and uncomplicated skin infections.

Cefprozil is a second-generation oral cephalosporin with broad-spectrum bactericidal activity. It provides enhanced stability against certain beta-lactamases and active coverage against Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis. Indicated for acute sinusitis, otitis media, secondary bacterial infections of acute bronchitis, community-acquired pneumonia, and uncomplicated skin infections.

Cefprozil is a second-generation oral cephalosporin with broad-spectrum bactericidal activity. It provides enhanced stability against certain beta-lactamases and active coverage against Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae, and Moraxella catarrhalis. Indicated for acute sinusitis, otitis media, secondary bacterial infections of acute bronchitis, community-acquired pneumonia, and uncomplicated skin infections.

Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.

Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.

Cefixime and Moxifloxacin combination pairs a 3rd-generation oral cephalosporin with a respiratory fluoroquinolone. Provides enhanced dual coverage against typical and atypical respiratory pathogens, resistant Gram-negative bacilli, and anaerobes. Indicated for severe or refractory community-acquired pneumonia, acute exacerbations of chronic bronchitis, and complicated polymicrobial infections.

Cefpodoxime Proxetil and Ofloxacin is a broad-spectrum combination of an oral 3rd-generation cephalosporin prodrug and a second-generation fluoroquinolone. Cefpodoxime blocks cell wall synthesis while ofloxacin halts DNA replication and transcription via bacterial DNA gyrase and topoisomerase IV inhibition. Indicated for mixed and resistant respiratory tract infections, enteric fever, and complicated skin or urinary infections.

Cefadroxil is a first-generation oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis. It possesses a prolonged plasma half-life compared to cephalexin, allowing once- or twice-daily dosing. Indicated for streptococcal pharyngitis/tonsillitis, uncomplicated urinary tract infections, and mild-to-moderate skin and skin structure infections.

Ceftazidime and Avibactam is an advanced carbapenem-sparing antimicrobial agent. Ceftazidime is an anti-pseudomonal third-generation cephalosporin, and avibactam is a novel non-beta-lactam beta-lactamase inhibitor that inhibits class A (including KPC carbapenemases), class C (AmpC), and certain class D (OXA-48) beta-lactamases. Indicated for complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.

Faropenem and Potassium Clavulanate is an oral penem antibiotic combined with a beta-lactamase inhibitor. Faropenem exhibits high stability against many bacterial beta-lactamases and binds PBPs with high affinity to block bacterial cell wall synthesis; clavulanic acid broadens this spectrum against ESBL-producing organisms. Indicated for community-acquired respiratory tract infections (sinusitis, bronchitis, pneumonia), complicated urinary tract infections, and resistant skin infections.

Lincomycin is a natural lincosamide antibiotic produced by Streptomyces lincolnensis. It binds to the 50S subunit of the bacterial ribosome, inhibiting peptide bond formation. Indicated for serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci in patients allergic to penicillins or when other antibiotics are inappropriate.

Lincomycin is a natural lincosamide antibiotic produced by Streptomyces lincolnensis. It binds to the 50S subunit of the bacterial ribosome, inhibiting peptide bond formation. Indicated for serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci in patients allergic to penicillins or when other antibiotics are inappropriate.

Penicillin G (Benzylpenicillin) is a natural beta-lactam bactericidal antibiotic. It acts by interfering with bacterial cell wall synthesis during active bacterial multiplication through binding to PBPs. Highly active against Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, Treponema pallidum, and Corynebacterium diphtheriae. Indicated for rheumatic fever prophylaxis, streptococcal pharyngitis, syphilis, and Vincent's stomatitis.

Penicillin G (Benzylpenicillin) is a natural beta-lactam bactericidal antibiotic. It acts by interfering with bacterial cell wall synthesis during active bacterial multiplication through binding to PBPs. Highly active against Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, Treponema pallidum, and Corynebacterium diphtheriae. Indicated for rheumatic fever prophylaxis, streptococcal pharyngitis, syphilis, and Vincent's stomatitis.

Cefixime, Cloxacillin (Extended Release), and Lactic Acid Bacillus is a broad-spectrum anti-infective formulation. Cefixime delivers extended Gram-negative coverage, cloxacillin resists staphylococcal penicillinases to eradicate resistant Gram-positive staphylococci, and probiotic Lactic Acid Bacillus restores intestinal flora. Indicated for mixed respiratory infections, cellulitis, surgical wound infections, and ENT infections.

Neomycin Sulphate, Polymyxin B Sulphate, and Bacitracin Zinc is a triple-antibiotic topical powder providing broad bactericidal synergy. Neomycin inhibits 30S protein synthesis in aerobic bacteria; Polymyxin B binds and disrupts outer Gram-negative bacterial membranes; and Bacitracin inhibits cell wall synthesis in Gram-positive cocci. Indicated for prevention and treatment of superficial bacterial skin infections in minor cuts, abrasions, lacerations, burns, and surgical wounds.

Ofloxacin and Metronidazole oral suspension is a dual antimicrobial formulation for mixed paediatric and adult gastrointestinal and systemic infections. Ofloxacin inhibits bacterial DNA gyrase, while metronidazole disrupts anaerobic and protozoal helical DNA structure. Indicated for bacterial and amoebic diarrhea, dysentery, giardiasis, and mixed aerobic-anaerobic infections.

Cefazolin Sodium is a first-generation parenteral cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis. Considered the gold-standard drug of choice for surgical antimicrobial prophylaxis across clean and clean-contaminated surgical procedures, as well as treatment of methicillin-susceptible Staphylococcus aureus (MSSA) and streptococcal bacteremia, endocarditis, and severe skin and soft tissue infections.

Cefazolin Sodium is a first-generation parenteral cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis. Considered the gold-standard drug of choice for surgical antimicrobial prophylaxis across clean and clean-contaminated surgical procedures, as well as treatment of methicillin-susceptible Staphylococcus aureus (MSSA) and streptococcal bacteremia, endocarditis, and severe skin and soft tissue infections.

Cefazolin Sodium is a first-generation parenteral cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis. Considered the gold-standard drug of choice for surgical antimicrobial prophylaxis across clean and clean-contaminated surgical procedures, as well as treatment of methicillin-susceptible Staphylococcus aureus (MSSA) and streptococcal bacteremia, endocarditis, and severe skin and soft tissue infections.

Clindamycin Phosphate (1% w/w gel) is a topical lincosamide antibiotic. It is hydrolyzed by skin phosphatases to active clindamycin, which inhibits protein synthesis in Cutibacterium acnes and reduces free fatty acid levels in surface sebum. Indicated for inflammatory acne vulgaris.

Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.

Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.

Cefepime is a fourth-generation parenteral cephalosporin bactericidal antibiotic. Its zwitterionic structure allows rapid penetration through Gram-negative bacterial outer membrane porins, providing broad coverage against both Gram-positive organisms (MSSA, streptococci) and Gram-negative bacilli, including Pseudomonas aeruginosa and AmpC-producing Enterobacteriaceae. Indicated for empirical monotherapy in febrile neutropenia, severe hospital-acquired pneumonia, complicated intra-abdominal infections, and complicated pyelonephritis.

Cefepime and Tazobactam is an advanced parenteral combination of a fourth-generation cephalosporin and a beta-lactamase inhibitor. Cefepime penetrates the outer bacterial membrane rapidly and possesses low affinity for AmpC beta-lactamases, while tazobactam neutralizes extended-spectrum beta-lactamases (ESBLs). Indicated for severe nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and multi-drug resistant urinary sepsis.

Minocycline is a potent, highly lipophilic second-generation tetracycline derivative. It penetrates tissues, sebaceous glands, and the central nervous system rapidly, where it inhibits bacterial protein synthesis via 30S ribosomal binding. Also exhibits anti-inflammatory and immunomodulatory activity. Indicated for moderate-to-severe inflammatory acne vulgaris, multidrug-resistant Acinetobacter baumannii infections, meningococcal carrier state prophylaxis, and susceptible skin/soft tissue infections.

Minocycline is a potent, highly lipophilic second-generation tetracycline derivative. It penetrates tissues, sebaceous glands, and the central nervous system rapidly, where it inhibits bacterial protein synthesis via 30S ribosomal binding. Also exhibits anti-inflammatory and immunomodulatory activity. Indicated for moderate-to-severe inflammatory acne vulgaris, multidrug-resistant Acinetobacter baumannii infections, meningococcal carrier state prophylaxis, and susceptible skin/soft tissue infections.

Minocycline is a potent, highly lipophilic second-generation tetracycline derivative. It penetrates tissues, sebaceous glands, and the central nervous system rapidly, where it inhibits bacterial protein synthesis via 30S ribosomal binding. Also exhibits anti-inflammatory and immunomodulatory activity. Indicated for moderate-to-severe inflammatory acne vulgaris, multidrug-resistant Acinetobacter baumannii infections, meningococcal carrier state prophylaxis, and susceptible skin/soft tissue infections.

Minocycline is a potent, highly lipophilic second-generation tetracycline derivative. It penetrates tissues, sebaceous glands, and the central nervous system rapidly, where it inhibits bacterial protein synthesis via 30S ribosomal binding. Also exhibits anti-inflammatory and immunomodulatory activity. Indicated for moderate-to-severe inflammatory acne vulgaris, multidrug-resistant Acinetobacter baumannii infections, meningococcal carrier state prophylaxis, and susceptible skin/soft tissue infections.

Minocycline is a potent, highly lipophilic second-generation tetracycline derivative. It penetrates tissues, sebaceous glands, and the central nervous system rapidly, where it inhibits bacterial protein synthesis via 30S ribosomal binding. Also exhibits anti-inflammatory and immunomodulatory activity. Indicated for moderate-to-severe inflammatory acne vulgaris, multidrug-resistant Acinetobacter baumannii infections, meningococcal carrier state prophylaxis, and susceptible skin/soft tissue infections.